These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2515615)

  • 21. The effect of nitric oxide donors on the release of plasminogen activator inhibitor (PAI) from rabbit platelets in vitro.
    Korbut R; Marcinkiewicz E; Cieślik K; Gryglewski RJ
    J Physiol Pharmacol; 1995 Mar; 46(1):37-44. PubMed ID: 7599336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Influence of aging and circadian fluctuation of fibrinolytic factors to the responses of these factors during venous occlusion test in healthy subjects].
    Motohashi F; Masui Y; Kamogawa A; Hayashi T; Miyake F; Murayama M; Sugai J; Yasumuro Y
    Rinsho Byori; 1992 Feb; 40(2):172-8. PubMed ID: 1583790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of correlation between blood fibrinolysis and the immediate or post-operative blood loss in transurethral resection of the prostate.
    Nielsen JD; Gram J; Fabrin K; Holm-Nielsen A; Jespersen J
    Br J Urol; 1997 Jul; 80(1):105-10. PubMed ID: 9240188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome.
    Vaziri ND; Gonzales EC; Shayestehfar B; Barton CH
    J Lab Clin Med; 1994 Jul; 124(1):118-24. PubMed ID: 7518491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DDAVP releases tPA in correlation with a fall in platelet serotonin in uraemic patients.
    Malyszko J; Malyszko JS; Azzadin A; Mysliwiec M; Buczko W
    Thromb Res; 1992 Nov; 68(3):303-8. PubMed ID: 1471076
    [No Abstract]   [Full Text] [Related]  

  • 26. Different tissue plasminogen activator release in the arm and leg during venous occlusion is equalized after DDAVP infusion.
    Keber D; Stegnar M; Kluft C
    Thromb Haemost; 1990 Feb; 63(1):72-5. PubMed ID: 2111049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Study on fibrinolysis and platelet function].
    Deguchi K; Murashima S; Nishikawa M; Shirakawa S
    Nihon Rinsho; 1992 Feb; 50(2):297-302. PubMed ID: 1613983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selected parameters of fibrinolysis system in patients with dermatitis herpetiformis.
    Wankiewicz A; Iwan-Zietek I; Kotschy M; Gwieździński Z
    Med Sci Monit; 2002 Mar; 8(3):CR189-92. PubMed ID: 11887034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients.
    Grant PJ; Stickland MH; Booth NA; Prentice CR
    Diabet Med; 1991 May; 8(4):361-5. PubMed ID: 1713132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous pressure and t-PA antigen release during venous occlusion of upper and lower limbs.
    Haaland AK; Skjønsberg OH; Thaulow E; Gjønnes G; Godal HC
    Thromb Res; 1989 Nov; 56(3):485-90. PubMed ID: 2515614
    [No Abstract]   [Full Text] [Related]  

  • 31. Occurrence of components of fibrinolysis pathways in situ in neoplastic and nonneoplastic human breast tissue.
    Costantini V; Zacharski LR; Memoli VA; Kudryk BJ; Rousseau SM; Stump DC
    Cancer Res; 1991 Jan; 51(1):354-8. PubMed ID: 1846311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abnormal plasma fibrinolysis in patients with rheumatoid arthritis and impaired endothelial fibrinolytic response in those complicated by vasculitis.
    Lau CS; McLaren M; Hanslip J; Kerr M; Belch JJ
    Ann Rheum Dis; 1993 Sep; 52(9):643-9. PubMed ID: 8239758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlations between t-PA and PAI-1 antigen and activity and t-PA/PAI-1 complexes in plasma of control subjects and of patients with increased t-PA or PAI-1 levels.
    Alessi MC; Juhan-Vague I; Declerck PJ; Anfosso F; Gueunoun E; Collen D
    Thromb Res; 1990 Dec; 60(6):509-16. PubMed ID: 2127964
    [No Abstract]   [Full Text] [Related]  

  • 34. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications.
    Lucore CL; Sobel BE
    Circulation; 1988 Mar; 77(3):660-9. PubMed ID: 2449299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hypofibrinolysis after venous occlusion in patients treated with long-term hemodialysis].
    Opatrný K; Vít L; Opatrná S; Sulková S; Bodláková B
    Cas Lek Cesk; 1994 May; 133(11):346-9. PubMed ID: 8004664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets.
    Erickson LA; Ginsberg MH; Loskutoff DJ
    J Clin Invest; 1984 Oct; 74(4):1465-72. PubMed ID: 6434594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Current developments in fibrinolytic therapy].
    Rijken DC
    Ned Tijdschr Geneeskd; 1985 Sep; 129(37):1768-72. PubMed ID: 3934567
    [No Abstract]   [Full Text] [Related]  

  • 38. [Recent progress in fibrinolytic mechanism].
    Yasukouchi T
    Rinsho Byori; 1986 Mar; 34(3):235-46. PubMed ID: 3086600
    [No Abstract]   [Full Text] [Related]  

  • 39. Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor.
    Ridker PM; Vaughan DE; Stampfer MJ; Manson JE; Shen C; Newcomer LM; Goldhaber SZ; Hennekens CH
    Circulation; 1992 May; 85(5):1822-7. PubMed ID: 1572039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibrinolytic response in normal subjects to venous occlusion and DDAVP infusion.
    Cugno M; Uziel L; Fabrizi I; Bottasso B; Maggiolini F; Agostoni A
    Thromb Res; 1989 Dec; 56(5):625-34. PubMed ID: 2516662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.